SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

08 Feb 2024 Evaluate
An increase of about 83.37% to Rs. 314.15 millions in the topline was observed for the quarter ended December 2023. The topline stood at Rs. 171.32 millions during the similar quarter previous year.The Total Profit for the quarter ended December 2023 of Rs. 13.64 millions grew from Rs.-102.14 millionsOperating profit for the quarter ended December 2023 rose to 63.77 millions as compared to 33.33 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 314.15 171.32 83.37 794.12 611.37 29.89 805.93 1643.49 -50.96
Other Income 5.25 11.14 -52.87 12.57 28.37 -55.69 34.52 27.20 26.91
PBIDT 63.77 33.33 91.33 136.02 157.07 -13.40 190.52 1002.19 -80.99
Interest 12.59 30.42 -58.61 37.63 87.57 -57.03 115.70 199.21 -41.92
PBDT 51.18 -66.06 -177.48 97.94 -0.85 -11622.35 3.08 756.30 -99.59
Depreciation 27.17 33.25 -18.29 95.15 101.94 -6.66 135.16 153.89 -12.17
PBT 24.01 -99.31 -124.18 2.79 -102.79 -102.71 -132.08 602.41 -121.93
TAX 10.37 2.83 266.43 9.27 0.04 23075.00 0.78 203.38 -99.62
Deferred Tax 1.27 -2.72 -146.69 -3.18 -5.51 -42.29 -1.29 203.38 -100.63
PAT 13.64 -102.14 -113.35 -6.48 -102.83 -93.70 -132.86 399.03 -133.30
Equity 330.90 286.90 15.34 330.90 286.90 15.34 306.90 286.90 6.97
PBIDTM(%) 20.30 19.45 4.34 17.13 25.69 -33.33 23.64 60.98 -61.23

Lyka Labs Share Price

65.10 3.10 (5.00%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×